Asset
NARAZACICLIB
TRAWS PHARMA INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05705505 | phase1_2 | unknown | 2023-03-29 | 2026-01-01 | Traws Pharma, Inc. | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies |
| NCT04739293 | phase1 | unknown | 2021-05-13 | 2024-10-01 | Traws Pharma, Inc. | Study of ON 123300 in Patients With Advanced Cancer |
FDA applications (0)
This company has no applications containing this asset.